Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RB-RQ007
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Capital Venture Capital Fund
Deal Size : $66.0 million
Deal Type : Series C Financing
Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio
Details : The funding is inted boost company's siRNA Portfolio.
Product Name : RB-RQ007
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : RB-RQ007
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Capital Venture Capital Fund
Deal Size : $66.0 million
Deal Type : Series C Financing